Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2455

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2455). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622455)

Label for Lisdexamfetamine Dimesylate Capsules 40 mg, oral dosage form, in a package of 100 capsules. The label shows the NDC 72162-2455-1 and indicates the product is Rx only. It is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Purdue Pharma L.P. Storage conditions and QR codes for package insert and dosage information are also present.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

Chemical structure diagram of lisdexamfetamine dimesylate, showing its molecular components and sulfonic acid groups.*

FDA Label Image

Figure 1 (Lisdexcaps 02)

A forest plot chart illustrating the fold change and 90% confidence intervals for Cmax and AUC pharmacokinetic parameters of Lisdexamfetamine Dimesylate across various special populations, including gender, age groups (65-74 years and 75+ years), and levels of renal impairment (mild, moderate, severe, end-stage renal disease). The x-axis shows the change relative to reference values from 0 to 2.5.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

A chart depicting fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of Guanfacine, Venlafaxine, and Omeprazole. The x-axis shows change relative to reference from 0.0 to 2.0, with data points indicating the degree of change and corresponding 90% confidence intervals.*

FDA Label Image

Figure 3 (Lisdexcaps 04)

A forest plot chart depicting pharmacokinetic (PK) fold changes and 90% confidence intervals for various interacting drugs relative to reference values. The chart includes drugs such as Guanfacine, Venlafaxine, Caffeine, Dextromethorphan, Omeprazole, and Midazolam, with data points representing Cmax and AUC changes along the x-axis ranging from 0.0 to 2.0 fold change.*

FDA Label Image

Figure 4 (Lisdexcaps 05)

This line graph compares LS Mean SKAMP Deportment Scores over time post-dose (hours) between Lisdexamfetamine and placebo. The x-axis indicates time from -0.5 to 13 hours, while the y-axis shows deportment scores from 0.1 to 2.0. Two lines represent placebo (dashed) and lisdexamfetamine (solid), with error bars at each time point indicating standard error.*

FDA Label Image

Figure 5 (Lisdexcaps 06)

A line graph comparing the proportion of subjects with relapse or treatment failure (%) over time in days after randomization between Lisdexamfetamine and placebo groups. The graph shows a lower proportion for Lisdexamfetamine versus placebo across 50 days, with the placebo group reaching about 70% relapse or failure.*

FDA Label Image

Figure 6 (Lisdexcaps 07)

A line graph showing LS Mean PERMP Total Scores over time post-dose (hours) comparing Lisdexamfetamine and Placebo. Lisdexamfetamine scores increase sharply from baseline and maintain higher values across 14 hours, while Placebo shows lower and more gradual increase. Error bars represent standard error.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

A line graph showing the proportion of subjects with relapse or treatment failure over time (days after randomization) comparing Lisdexamfetamine and placebo. The x-axis represents time up to 40 days, and the y-axis shows the percentage of subjects. The Lisdexamfetamine group shows a much lower proportion of relapse or treatment failure compared to the placebo group throughout the period.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

A Kaplan-Meier curve chart depicting the proportion of subjects with release (%) over time (days after randomization) comparing Lisdexamfetamine and placebo groups. The chart includes a legend clarifying which line corresponds to Lisdexamfetamine and placebo, and below the x-axis, the number of subjects at risk over time in each group is displayed.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.